Cancer and thrombosis: recent advances
2008
Cancer and Thrombosis: Recent Advances
publication
Evidence: moderate
Author Information
Author(s): Solymoss S., Richard J. Ablin, Phil Gold
Primary Institution: McGill University
Hypothesis
How should thromboprophylaxis for cancer patients be optimized?
Conclusion
Long-term low molecular weight heparin therapy improves outcomes for cancer patients with venous thromboembolism.
Supporting Evidence
- Long-term low molecular weight heparin therapy is associated with improved patient outcomes.
- Cancer patients with venous thromboembolism are at increased risk of mortality.
- Recent guidelines emphasize the importance of optimizing anticoagulation management in cancer patients.
Takeaway
Cancer patients can get blood clots, which can be dangerous, but using a special medicine called low molecular weight heparin can help them feel better and live longer.
Limitations
The study does not specify the exact populations or conditions under which the findings apply.
Participant Demographics
Cancer patients, particularly those with advanced cancer and specific types like pancreatic, stomach, brain, lung, and hematologic malignancies.
Want to read the original?
Access the complete publication on the publisher's website